EDAP Announces Reimbursement Approval in Switzerland for the Use of High-Intensity Focused Ultrasound (HIFU) in the Treatment of Prostate CancerGlobeNewsWire • 07/26/23
EDAP Announces Major Presence at Upcoming Annual Meeting of the American Urological Association (AUA)GlobeNewsWire • 04/21/23
EDAP Announces Live Procedure Broadcast of Focal One High Intensity Focused Ultrasound (HIFU) to Global Clinical AudienceGlobeNewsWire • 04/10/23
EDAP Reports Record Fourth Quarter and Full-Year 2022 Results and Announces Leadership Succession Plan to Develop Global Group StrategyGlobeNewsWire • 03/30/23
EDAP Presents Positive Results from Non-Inferiority Study Comparing Outcomes of Focal One HIFU Versus Radical Prostatectomy at EAU23GlobeNewsWire • 03/21/23
EDAP to Announce Fourth Quarter and Full-Year 2022 Financial Results on Thursday, March 30thGlobeNewsWire • 03/09/23
EDAP: Potential Crossover Of HIFU To Endometriosis Additional Inflection PointsSeeking Alpha • 02/03/23
EDAP Announces Positive Results from Phase 2 Study Evaluating Therapeutic High-Intensity Focused Ultrasound (HIFU) for the Treatment of Rectal EndometriosisGlobeNewsWire • 01/31/23
EDAP Appoints Medical Capital Equipment Finance Veteran Ken Mobeck as Chief Financial Officer of Company's U.S. SubsidiaryGlobeNewsWire • 12/06/22
EDAP Announces Approval to Initiate Randomized Clinical Trial Evaluating Focal One® as a Potential Treatment for Rectal Deep Infiltrating EndometriosisGlobeNewsWire • 11/30/22
EDAP TMS S.A. (EDAP) Is a Great Choice for 'Trend' Investors, Here's WhyZacks Investment Research • 11/30/22